Background. Since the recognition that human immunodeficiency virus is transmissible by blood transfusion there has been increasing public and professional support for autologous blood donations before elective surgery. Autologous blood donation is, however, a more expensive process than the donation of allogeneic blood by community volunteers. Furthermore, there have been recent improvements in the safety of the volunteer blood supply.
T HE epidemic of the acquired immunodeficiency syndrome (AIDS) has increased concern about the risk of transmitting infectious diseases through blood transfusion. In response to this concern, there has been a dramatic increase in preoperative autologous blood donations over the past decade. [1] [2] [3] [4] Although sensationalized reports of the dangers of blood transfusion continue in the lay press, 5 there have been great improvements in the safety of the blood supply, primarily because of rigorous donor screening and sensitive serologic tests for the human immunodeficiency virus (HIV) and for hepatitis C virus. 6 Autologous blood is more costly than allogeneic blood. Its donation entails greater administrative expense and a longer, more labor-intensive process of collection. Moreover, the frequency of positive tests for infectious disease in autologous units 7, 8 has raised questions about the safety of transfusing unused autologous units into patients other than the donor. Because of this concern, 85 percent of U.S. blood centers do not retain unused autologous units for other patients, but rather destroy them. 9 This practice has substantially raised the cost of autologous transfusion.
The current national debate on health care reform makes this an appropriate time to analyze the cost effectiveness of autologous blood donation. In our study, we determined the costs of providing patients with autologous blood and used decision-analysis techniques to calculate the cost effectiveness of substituting autologous for allogeneic blood. We also analyzed the value of various strategies to minimize the costs of autologous-donation programs.
M ETHODS

Calculation of Cost Effectiveness
We defined the incremental cost effectiveness of the use of autologous blood as the net change in the amount of health care resources required to collect and transfuse an autologous unit, instead of an allogeneic unit, divided by the net change in the amount of health benefits resulting from this substitution. A higher cost-effectiveness value thus defined represents a lower degree of cost effectiveness.
Costs were assessed from a social perspective and were considered to reflect only the expenditure of health care resources, not indirect expenses such as wages or productivity lost because of illness or death. Effectiveness was expressed in quality-adjusted years of life saved by the avoidance of transfusion-associated infectious disease.
Because some of the costs and benefits in our model were assumed to occur in the future, we discounted their future value at a rate of 5 percent per year to estimate present value. 10, 11 We used Excel spreadsheet software (Excel 4.0, Microsoft, Redmond, Wash.) to calculate cost effectiveness. logeneic blood due to factors such as positive tests or markers for infectious disease, units being outdated, and acute transfusion reactions.
Cost Variables
Direct Costs
We studied the blood-donation process for donors of both types of blood to determine the resources required for the recruitment, screening, and interviewing of donors; administrative record-keeping; and phlebotomy. To estimate other direct costs we relied on a survey conducted by the UCLA Division of Management Sciences that examined the actual costs to the university's blood center of infectious-disease and compatibility testing, blood processing, and inventory management. On the basis of these studies, we estimate that the average direct costs of autologous and allogeneic units at UCLA in 1992 were $198.04 and $149.80, respectively -a difference of $48.24 per unit. A breakdown of these cost estimates is shown in Table 2 .
Cost of Discarded Units
In order that the cost of discarded units be reflected in the average cost of a unit transfused, we divided the direct cost per unit by the rate at which units collected were actually transfused. For example, dividing the direct cost of an autologous unit, $198 (Table 2) , by the rate of units used in hip surgery, 0.84 (Table 1) , yielded $236 as the cost of a transfused autologous unit for that procedure. Repeating these calculations for the other procedures studied resulted in perunit costs of $275 for coronary-artery bypass grafting, $762 for hysterectomy, and $4,951 for transurethral prostatectomy.
The discarding of units was also a factor in determining the total cost of a transfused unit of allogeneic blood. We calculated that the cost of discarded units added another $9.72 to the average cost of each unit transfused. We also added $3.87 to represent the cost of cross-matching units of allogeneic blood that were not transfused into their initially intended recipients. This brought the total indirect cost of unused blood to $13.59 per unit transfused.
Costs of Treating Complications of Transfusion
For each of several viruses transmissible by transfusion, we estimated the per-unit probability of infection in donated allogeneic blood ( Table 3 ). We also estimated the per-unit probability that patients receiving transfusions of infected blood would have each of the forms of disease associated with the given virus ( Table 3 ). We then multiplied these two per-unit probabilities by the estimated costs of treating each disease.
We discounted the costs of treating patients with transfusion-associated hepatitis on the basis of a median life expectancy of 18 years. 12 Using this technique we estimated that the lifetime cost of treating transfusion-associated hepatitis 13 added $4.05 to the cost of each allogeneic blood unit. Similarly, the cost of treating HIV infection added another $0.63 per allogeneic unit, on the basis of an estimated lifetime treatment cost of $119,000, 14 multiplied by our base-line estimate of the per-unit risk of HIV (Table 3 ) and discounted over nine years of expected survival.
We were unable to find estimates of the cost of treating diseases caused by human T-cell lymphotropic virus types I and II (HTLV-I and HTLV-II). However, even if we assumed that these costs were as high as those incurred for treating HIV infection, they would add only about five cents per unit, because the probability that these complications will develop is so low ( Table 3) . We did not model the costs of other transfusion-acquired infectious diseases because of their extreme rarity in the United States. 6 On the basis of practice at UCLA, we estimated that the average cost of diagnosing an acute transfusion reaction added seven cents per unit in undiscounted costs. Delayed hemolytic transfusion reactions were excluded from consideration because they are unusual and rarely cause serious morbidity. 15 Costs of treating acute hemolytic transfusion reactions were also excluded, since these happen most commonly when a unit of blood is transfused into the wrong patient. 15, 16 The risk of this type of human error is independent of the category of blood donation.
We chose not to model the possible immunomodulating effects of allogeneic transfusion. [17] [18] [19] [20] [21] [22] The current evidence of these effects comes primarily from retrospective studies, and not all investigators agree that a causal link has been established. [23] [24] [25] Taken together, transfusion-related complications added $4.80 to the cost of each unit of blood. Adding this indirect cost, the $13.59 indirect cost of unused blood, and the direct cost of $149.80 yielded a total cost of transfused allogeneic blood of $168.19 per unit.
Effectiveness Variables
We used published estimates of the probabilities, per unit of blood, of contracting transfusion-associated infections and of the likelihood of various disease outcomes resulting from those infections. The values assigned to the effectiveness variables in our model were based, whenever possible, on the best estimates available, but when assumptions or estimates were equivocal, we assigned values that tended to bias our results in favor of autologous donation. For example, in our base-line analysis we used 0.0003 and 0.000005 as the risks of transmission of hepatitis C virus 26 and of hepatitis B virus, 6 respectively, along with the estimates of the probability of various outcomes 13, 27 presented in Table 3 . In the largest prospective study to date of transfusion-related hepatitis, however, mortality from all causes after an average follow-up of 18 years was the same (51 percent) for transfusion recipients in whom hepatitis developed as for a matched group of transfusion recipients in whom hepatitis did not develop. 13 Despite this finding, we made the assumption -in favor of autologous donations -that there is excess mortality of 0.9 percent per year among transfusion recipients who contract hepatitis. We assumed that all those in whom fulminant hepatitis develops die immediately after transfusion. Recent estimates of the risk of infection with HIV are as low as 1 infected unit per 225,000. 6 We used a higher estimate of 1 unit per 150,000 (0.0000067). 28 Our undiscounted estimates of the average latency period from the time of infection with HIV to the development of AIDS 29 and the mean survival time after the diagnosis of AIDS are seven and two years, respectively.
The risk of transmission of HTLV-I or HTLV-II through allogeneic transfusion is currently estimated to be 1 infected unit per 60,000 (0.000017), with a maximally estimated 4 percent lifetime risk that clinically active disease will develop in patients who become infected. 30, 31 Base-line life expectancies were obtained from U.S. vital-statistics life-table data 32 and discounted at a rate of 5 percent per year. The effect of transfusion complications on discounted life expectancies was calculated with use of the 0.75 Mixed Declining Exponential Approximation of Life Expectancy. 33 We adjusted our life-expectancy calculations to reflect the relative desirability of various states of health associated with possible complications of allogeneic transfusion. We then expressed the outcomes in qualityadjusted years of life. The values assigned to specific health states in our analysis (Table 3) represented our consensus after reviewing the relevant medical literature. [34] [35] [36] [37] 
Sensitivity Analysis
The variables in our decision-analysis model were analyzed over a range of values in a process known as sensitivity analysis. This was done to determine the stability of our results and to gauge the effects of uncertainty in the values we assigned to these variables. We also analyzed the potential effect of some suggestions to lower the cost of autologous-donation programs: reduced testing for blood compatibility and infectious disease, 38 the addition of unused units to the allogeneic blood supply, 9, 39 and the use of collection-schedule guidelines. 40 Finally, to demonstrate how our model might be generalized, we analyzed the cost effectiveness of autologous donation for hypothetical patients of various ages undergoing procedures with differing percentages of discarded units of blood.
R ESULTS
The added cost of substituting an autologous unit for an allogeneic one ranged from $68 to $4,783 in the procedures we examined ( Table 4 ). The higher cost of autologous blood, as well as its variation according to procedure, results mainly from the cost of discarded units. By comparison, the direct costs of producing an autologous unit, which we estimated to be $48 higher than those for a unit of allogeneic blood, made a smaller contribution to the overall cost difference in three of the four procedures.
The incremental effectiveness of autologous blood was small in all four procedures, ranging from 0.0002 to 0.00044 quality-adjusted year of life (about two to four hours) per unit ( Table 4 ). The variation in effectiveness was a function of the different life expectancies of the average patients undergoing each procedure.
Finally, the incremental cost effectiveness, expressed as dollars per quality-adjusted year of life saved, varied from $235,000 to over $23 million (Table 4 ). Sensitivity analyses revealed that these results were not substantially altered by uncertainty in the values of any variable in the model. In fact, increasing the risk of contracting hepatitis C -the most sensitive risk variable in our model -by as much as 50 percent still resulted in a high cost-effectiveness value of $167,000 per quality-adjusted year of life, even in hip surgery, the procedure we examined that was most likely to favor the use of autologous blood ( Table 5 ).
Cost savings from reduced testing for blood compatibility and infectious diseases would have the most pronounced effects in hip surgery and coronary-artery bypass surgery, the procedures using the most transfused blood. Even for these, though, the resulting cost-effectiveness values were $87,000 and $263,000 per qualityadjusted year of life, respectively ( Table 5 ). Not surprisingly, saving unneeded autologous units for nondonor recipients would most improve cost effectiveness in the procedures in which autologous donations are least likely to be used by the donor. However, implementing such a policy would still result in costeffectiveness values in the range of $163,000 to over $1 million per quality-adjusted year of life (Table 5 ).
Applying the principles of a "schedule of optimal preoperative collection of autologous blood," as described by Axelrod et al., 40 would increase the amount of autologous blood collected and subsequently discarded, thereby dramatically elevating the cost-effectiveness values for most procedures. For example, donating five units would protect 90 percent of patients undergoing hip surgery from exposure to allogeneic blood, but would also result in the discard of 41 percent of the units and cost $580,000 per quality-adjusted year of life saved ( Table 5 ). Table 6 demonstrates the effect on the cost effectiveness of autologous donation of the patient's age and the percentage of units discarded. Autologous donation is more cost effective for younger patients. However, even for the youngest patients undergoing procedures in which the percentage of discarded units is as low as 15 percent, the cost-effectiveness value was at least $105,000 per quality-adjusted year of life.
D ISCUSSION
Discarded units are primarily responsible for the higher cost of autologous blood. The rates of use of blood units that we employed in our calculations were based on transfusion practice during one year at one institution. Such rates can change over time and vary from one institution to another, but we do not believe that the highest rate of use we found, 0.84, could be substantially improved. Because of the wide variation in the transfusion requirements of patients undergoing hipreplacement surgery -from 0 to 12 units -16 percent of autologous units were discarded in that procedure, despite the fact that the mean donation (3 units) was equal to the mean number of units transfused. The greater direct costs associated with the use of autologous units also made an important contribution to the unfavorable cost-effectiveness values that we found. A more labor-intensive donation process is primarily responsible for these higher costs. The scheduling of autologous donation requires the time of administrative personnel and physicians to coordinate donations with individual surgical schedules. Despite the abbreviated medical-history questionnaire used for autologous donors, their screening interviews take longer because autologous donors tend to have more involved medical histories than allogeneic donors. Potential autologous donors are also more likely to be asked to *QALY denotes quality-adjusted year of life. †HCV denotes hepatitis C virus. ‡As compared with allogeneic blood donation. §The schedule of optimal preoperative collection of autologous blood described by Axelrod et al. 40 recommends the donation of enough autologous units to ensure that 90 percent of patients avoid allogeneic transfusion. Given the transfusion practice at UCLA in 1992, five units would have been necessary for hip replacement, six units for bypass grafting, one unit for hysterectomy, and no units for prostatectomy. defer donation. They thus require more counseling about the reasons for deferral (e.g., intercurrent illness or low hematocrit) and the alternatives open to them. Finally, phlebotomy is a longer process for autologous donors, who tend to be older and more frail than allogeneic donors.
Labor-related direct costs may be greater at UCLA than at other institutions, but even when we halved our base-line estimate of the additional direct costs of autologous blood, the cost-effectiveness values were never lower than $135,000 per quality-adjusted year of life ( Table 5) .
Previous analyses of the cost effectiveness of autologous blood donation for hip surgery 41 and coronaryartery bypass grafting 42 used decision-analysis techniques similar to ours. Although this earlier work used estimates of direct costs based on Medicare cost-tocharge ratios, it produced results consistent with our own. These studies have been criticized for using hospital charge data to estimate true costs, 38 but their results support our conclusion that autologous blood donation is not as cost effective as many of its proponents believe.
Some transfusion-medicine specialists have suggested strategies to make this medical service more cost effective. 9, [38] [39] [40] We found that reducing testing for blood compatibility and the presence of infectious disease might substantially improve cost effectiveness. However, this strategy reduced the cost-effectiveness value to less than $100,000 per quality-adjusted year of life in only one procedure (Table 5 ). Furthermore, the actual cost savings from reduced testing would be limited to hospital-based blood centers, which collect only half the nation's autologous blood. 4 Exemptions from Food and Drug Administration testing requirements are possible only for units of autologous blood donated and transfused at the same institution.
The rather small effects of adding unused autologous units to the allogeneic blood supply ( Table 5 ) may seem especially surprising, given our finding that their destruction is the most important reason for the higher cost of autologous blood. However, because donors of autologous blood tend to have more medical problems than community volunteer donors, we estimated that only half these units would meet the strict requirements for infectious-disease testing and history taking that apply to allogeneic donation.
We may have actually overestimated the improvement in cost effectiveness resulting from the use of autologous blood for nondonor patients. Others have estimated that only 30 percent of these units would be suitable. 3 Moreover, we did not model the increased administrative costs that could be expected for labeling and maintaining two separate autologous-blood inventories (one eligible and one ineligible for use with other patients).
The perception and assessment of risk by the public, as well as by medical professionals, is a complex proc-ess. It is probably greatly influenced by media coverage that often focuses on the most negative and dramatic examples of complications of medical practices and procedures. 5 Studies, such as ours, that attempt to quantify the risks and benefits of blood transfusion could well be used as a starting point for more informed discussions between doctors and patients.
Our decision-analysis model could also be used to develop guidelines for more responsible use of this expensive medical practice. Some previous guidelines for autologous blood donation require only that a patient's hemoglobin be above a certain level. 2, 43 Others recommend donation from patients with at least a 10 percent probability of requiring transfusion. 9, 44 But these criteria promote donation in circumstances in which many units would be destroyed and where, according to our study, the cost per quality-adjusted year of life saved could be as high as several million dollars ( Table 6 ).
Our estimates of cost effectiveness reflect a social perspective, but they also have an economic impact at the institutional level. Under current Medicare reimbursement policies, discarded autologous blood units increase a hospital's unreimbursed expenses for performing surgery on Medicare patients. 45 Individual patients, anxious about the risks of allogeneic transfusions, may be willing to pay the added costs of autologous donation themselves. Whether society should be willing to pay to relieve this anxiety has yet to be resolved, despite those who challenge the insurance industry and the federal government to "recognize their responsibility to pay reasonable charges for the valuable service of autologous blood collection." 40 Although there is no currently accepted absolute standard by which the effectiveness of a medical intervention can be judged to be worth its cost, our analysis represents one method to assess various uses of limited health care resources. Society should consider whether its interests are best served by paying for autologous blood donations when other practices, already proved to be much more cost effective, have not yet been made universally available.
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